Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

United Therapeutics Corp (NASDAQ:UTHR)

169.36
Delayed Data
As of Jul 31
 +6.57 / +4.04%
Today’s Change
86.04
Today|||52-Week Range
190.29
+30.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$7.4B

Company Description

United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company operates in two business segments: Pharmaceuticals and Telemedicine. Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Contact Information

United Therapeutics Corp.
1040 Spring Street
Silver Spring Maryland 20910
P:(301) 608-9292
Investor Relations:
(202) 483-7000

Employees

Shareholders

Other institutional63.31%
Mutual fund holders52.35%
Individual stakeholders13.18%

Top Executives

Martine A. RothblattChairman & Co-Chief Executive Officer
Roger A. JeffsPresident, Co-Chief Executive Officer & Director
David ZaccardelliChief Operating Officer & Executive Vice President
James EdgemondChief Financial Officer & Treasurer
Shola OyewoleChief Information Officer